Goldman Sachs raised the firm’s price target on Sarepta Therapeutics to $223 from $215 and keeps a Buy rating on the shares. The FDA broadened the label for Elevidys in Duchenne muscular dystrophy from the accelerated approval in ambulatory 4-5 year-olds to include ambulatory and non-ambulatory patients at least four years old via traditional and accelerated approval, the analyst tells investors in a research note. The firm expects continued execution on the launch and remains positive on Sarepta’s outlook. It models for peak Elevidys revenue of $2.6B in 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Pfizer DMD gene therapy miss paves way for Sarepta, Solid Biosciences, says Citi
- Sarepta rises as Pfizer âdisappointingâ DMD results remove competitor overhang
- Pfizer failure eliminates DMD competitor for Sarepta, says Baird
- Pfizer’s ‘disappointing’ Phase 3 results positive for Sarepta, says Mizuho
- Pfizer failure removes overhang for Sarepta, says Barclays